203 related articles for article (PubMed ID: 29739080)
1. Serum Free Light Chain Predict Overall Survival and Response to Therapy in Patients with Newly Diagnosed Multiple Myeloma.
Meddour Y; Rahali MC; Belakehal SE; Ardjoun FZ; Chaib S; Djidjik R
Clin Lab; 2018 Apr; 64(4):551-558. PubMed ID: 29739080
[TBL] [Abstract][Full Text] [Related]
2. Further stratification of patients with multiple myeloma by International Staging System in combination with ratio of serum free κ to λ light chains.
Xu Y; Sui W; Deng S; An G; Wang Y; Xie Z; Yao H; Zhu G; Zou D; Qi J; Hao M; Zhao Y; Wang J; Chen T; Qiu L
Leuk Lymphoma; 2013 Jan; 54(1):123-32. PubMed ID: 22712834
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
[TBL] [Abstract][Full Text] [Related]
4. Using Both Lactic Dehydrogenase Levels and the Ratio of Involved to Uninvolved Free Light Chain Levels as Risk Factors Improves Risk Assessment in Patients With Newly Diagnosed Multiple Myeloma.
Guo Z; Li H; Geng Y; Cui J; Tang N; Li D
Am J Med Sci; 2018 Apr; 355(4):350-356. PubMed ID: 29661348
[TBL] [Abstract][Full Text] [Related]
5. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
van Rhee F; Bolejack V; Hollmig K; Pineda-Roman M; Anaissie E; Epstein J; Shaughnessy JD; Zangari M; Tricot G; Mohiuddin A; Alsayed Y; Woods G; Crowley J; Barlogie B
Blood; 2007 Aug; 110(3):827-32. PubMed ID: 17416735
[TBL] [Abstract][Full Text] [Related]
6. Serum free light chain response after 2 courses of induction chemotherapy predicts prognosis in myeloma patients.
Yağcı M; Karakaya F; Suyanı E; Haznedar R
Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):98-102. PubMed ID: 25441109
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation and comparison of prognostic value of serum free light chain ratio/difference in patients with newly diagnosed multiple myeloma].
Li L; Jiang H; Fu WJ; Du J; He HY; Lu J; An R; He J; Zhang H; Zhao YY; Wu H; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):321-326. PubMed ID: 31104445
[No Abstract] [Full Text] [Related]
8. Prognostic Value of Serum Free Light Chain in Multiple Myeloma.
El Naggar AA; El-Naggar M; Mokhamer el-H; Avad MW
Egypt J Immunol; 2015; 22(1):69-78. PubMed ID: 26415374
[TBL] [Abstract][Full Text] [Related]
9. Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients.
Barbee MS; Nooka A; Kaufman JL; Kim S; Chen Z; Heffner LT; Lonial S; Harvey RD
Cancer; 2015 Mar; 121(6):853-62. PubMed ID: 25377852
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens.
Tacchetti P; Cavo M; Rocchi S; Pezzi A; Pantani L; Brioli A; Testoni N; Terragna C; Zannetti BA; Mancuso K; Marzocchi G; Borsi E; Martello M; Rizzello I; Zamagni E
Leuk Lymphoma; 2016 Sep; 57(9):2058-64. PubMed ID: 26763357
[TBL] [Abstract][Full Text] [Related]
11. Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials.
Lopez-Anglada L; Cueto-Felgueroso C; Rosiñol L; Oriol A; Teruel AI; Lopez de la Guia A; Bengoechea E; Palomera L; de Arriba F; Hernandez JM; Granell M; Peñalver FJ; Garcia-Sanz R; Besalduch J; Gonzalez Y; Martinez RB; Hernandez MT; Gutierrez NC; Puerta P; Valeri A; Paiva B; Blade J; Mateos MV; San Miguel J; Lahuerta JJ; Martinez-Lopez J;
PLoS One; 2018; 13(9):e0203392. PubMed ID: 30192814
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests.
Heaney JLJ; Campbell JP; Griffin AE; Birtwistle J; Shemar M; Child JA; Gregory WM; Cairns DA; Morgan G; Jackson G; Drayson MT
Br J Haematol; 2017 Jul; 178(2):220-230. PubMed ID: 28573706
[TBL] [Abstract][Full Text] [Related]
13. [Effect of Serum Free Light Chain on Renal Function and Prognosis in Patients with Newly Diagnosed Multiple Myeloma].
Chen XD; Luo XF; Zu YP; Ye H; Li LL; Chen QL; Xie WZ; Yang T; Hu JD; Wei LX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Dec; 27(6):1862-1868. PubMed ID: 31839051
[TBL] [Abstract][Full Text] [Related]
14. Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma.
Iwama K; Chihara D; Tsuda K; Ugai T; Sugihara H; Nishida Y; Yamakura M; Takeuchi M; Matsue K
Eur J Haematol; 2013 Feb; 90(2):134-41. PubMed ID: 23210517
[TBL] [Abstract][Full Text] [Related]
15. [Clinical significance of serum free light chain in patients with multiple myeloma].
Zhang SS; Wu S; Qu XY; Xu J; Liu P; Lu H; Wu HX; Xu JR; Li JY; Chen LJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):930-5. PubMed ID: 23998588
[TBL] [Abstract][Full Text] [Related]
16. Robust Reference Intervals for Serum Kappa and Lambda Free Light Chains from a Multi Centre Study Population from Hyderabad, India: Myeloma Diagnostic Implications.
Mohammed N; Chandran PA; Kandregula M; Mattaparthi RD; Gundeti S; Volturi J; Darapuneni R; Raju SB; Dattatreya PS
Asian Pac J Cancer Prev; 2016; 17(5):2605-10. PubMed ID: 27268638
[TBL] [Abstract][Full Text] [Related]
17. [Test of Serum Free Light Chain and Its Clinical Significance in Light Chain Multiple Myeloma].
Song P; An ZM; Zhou XG; Li F; Wang LP; Zhao Q; Yu YP; Zhai YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1357-61. PubMed ID: 26524037
[TBL] [Abstract][Full Text] [Related]
18. [The roles of serum free light chain ratio in the diagnosis and prognosis of newly diagnosed multiple myeloma].
Wang PF; Xu Y; Yan S; Yao Y; Zheng HF; Ma L; Jin S; Xu Y; Gong FR; Zhou JZ; Chang HR; Fu CC
Zhonghua Xue Ye Xue Za Zhi; 2016 May; 37(5):377-82. PubMed ID: 27210871
[TBL] [Abstract][Full Text] [Related]
19. [Effect of Serum Free Light Chain Ratio and Normalization Ratio after Treatment on Diagnosis and Prognosis of Patients with Newly Diagnosed Multiple Myeloma].
Li ZQ; Tian WW; Guo YF; Ma LM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1245-1250. PubMed ID: 32798406
[TBL] [Abstract][Full Text] [Related]
20. Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy.
Alhaj Moustafa M; Rajkumar SV; Dispenzieri A; Gertz MA; Lacy MQ; Buadi FK; Hwa YL; Dingli D; Kapoor P; Hayman SR; Lust JA; Kyle RA; Kumar SK
Leukemia; 2015 Oct; 29(10):2033-8. PubMed ID: 25962523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]